Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Potential cardiotoxicity with mitoxantrone

F C Schell, H Y Yap, G Blumenschein

    Cancer Treatment Reports
    |August 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Association between autophagy and KRAS mutation with clinicopathological variables in colorectal cancer patients.

    The Malaysian journal of pathology·2021
    Same author

    A review of the Turned-down Onto Pericapsular-tissue Hemisectioned Amputated Toe (TOPHAT) flap for wound coverage during ray amputations of the toes.

    Foot (Edinburgh, Scotland)·2021
    Same author

    Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases.

    Annals of oncology : official journal of the European Society for Medical Oncology·2018
    Same author

    A multi-criteria analysis of options for energy recovery from municipal solid waste in India and the UK.

    Waste management (New York, N.Y.)·2015
    Same author

    Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC).

    Cancer treatment reviews·2011
    Same author

    Complications of thoracentesis.

    Internal medicine journal·2009
    Same journal

    Rhabdomyolysis associated with high-dose cytarabine.

    Cancer treatment reports·1987
    Same journal

    Acute laryngeal edema after single-dose irradiation and doxorubicin.

    Cancer treatment reports·1987
    Same journal

    Timing may be a critical factor in drug therapy.

    Cancer treatment reports·1987
    Same journal

    Prednimustine in advanced malignant melanoma: a phase II study.

    Cancer treatment reports·1987
    Same journal

    Phase II evaluation of diaziquone in pancreatic carcinoma: a Southwest Oncology Group Study.

    Cancer treatment reports·1987
    Same journal

    Teniposide in metastatic renal and bladder cancer: a Southwest Oncology Group Study.

    Cancer treatment reports·1987
    See all related articles

    Mitoxantrone shows antitumor potential but carries a risk of cardiotoxicity. Further trials require careful cardiac monitoring for patients receiving this chemotherapy agent.

    Area of Science:

    • Oncology
    • Cardiology
    • Pharmacology

    Background:

    • Mitoxantrone was developed as a novel chemotherapy agent with broad-spectrum antitumor activity.
    • The drug was designed to minimize cardiotoxicity, a common side effect of anthracyclines.

    Observation:

    • A Phase II clinical trial investigated mitoxantrone for refractory metastatic breast cancer.
    • Congestive heart failure was observed in 4 out of 31 high-risk patients.

    Findings:

    • The observed cardiotoxicity suggests mitoxantrone may not be devoid of cardiac risks.
    • The incidence of congestive heart failure warrants further investigation into mitoxantrone's cardiac safety profile.

    Implications:

    • Further clinical evaluation of mitoxantrone must include rigorous cardiac monitoring.

    Related Experiment Videos

  • Oncologists should be aware of the potential cardiotoxic effects of mitoxantrone in high-risk patients.